A Securities and Exchange ... Pfizer, alleging that the pharmaceutical giant lied about the effectiveness of its COVID-19 vaccine. More than 100 CEOs and business leaders in New York City are ...

In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of ...

The New York-based pharma giant generated adjusted earnings of $0.60 a share on revenue of $13.28B that grew 2.2% ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...

But is the stock still worth buying in hopes of a recovery over the long term? To answer that question in more detail, let's put this setback into context.

senior market strategist for the New York Stock Exchange. Sign up for Kiplinger's FREE Investing Weekly e-letter for stock, ETF and mutual fund recommendations, and other investing advice.

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...

Shares in Pfizer listed on the New York Stock Exchange, fell 2% on Monday having lost 31% of their value over the previous 12 ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Investing.com-- U.S. stocks started the new week in a muted fashion as investors hunkered down on Monday before a Federal ...